N/A N=13 Radiation Therapy in Treating Patients With Recurrent Breast Cancer
Breast Cancer
Primary: Ipsilateral Breast Tumor Recurrence Rates — 0; 0 percentage of participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=65 Radiation Therapy in Treating Women With Locally Recurrent Breast Cancer Previously Treated With Repeat Breast-Preserving Surgery
Breast Cancer
Primary: Number of Participants With Grade 3+ Treatment-related Skin, Fibrosis, and Breast Pain Adverse Events — 1 participants
N/A N=66 Intraoperative Radiotherapy After Local Recurrence in Breast Cancer
Breast Carcinoma
Primary: The Tolerance of RIOP (Intra Operative Radiotherapy) in Patients With Delayed Local Recurrences, After a Second Conservative Treatment of Breast Cancer — 34; 19…
Phase 2 N=24 SV-BR-1-GM in Metastatic or Locally Recurrent Breast Cancer
Breastcancer · Breast Neoplasm
Primary: Number of Patients With Treatment Emergent Adverse Events Occurring in Two or More Patients [Safety] — 24; 11; 8; 7 Participants
Phase 3 N=162 Adjuvant Chemotherapy in Treating Women Who Have Undergone Resection for Relapsed Breast Cancer; Chemotherapy as Adjuvant for LOcally Recurrent Breast Cancer
Breast Cancer
Primary: Disease-free Survival — 57; 69 percentage of participants
Phase 2 N=32 Carboplatin, Paclitaxel, and Bevacizumab in Treating Patients With Locally Recurrent or Metastatic Breast Cancer
Breast Cancer
Primary: Progression-free Survival — 16 Months
Phase 2 N=19 Mini-Allogeneic Peripheral Blood Progenitor Cell Transplantation For Recurrent or Metastatic Breast Cancer
Breast Cancer
Primary: Number of Participants With Tumor Response — 5; 9; 1; 3 participants
Phase 2 N=124 Tamoxifen Citrate in Treating Patients With Metastatic or Recurrent Breast Cancer
Breast Cancer · Stage IV Breast Cancer
Primary: Progression-free Survival by CYP2D6 Status in 2 Categories — 12.9; 6.9 months
Phase 2 N=103 Ixabepilone + Carboplatin Metastatic Breast Cancer
Metastatic Breast Cancer
Primary: Objective Response Rate (ORR) — 30.4; 34 percentage of participants
Phase 1 N=15 HER-2 Pulsed DC Vaccine to Prevent Recurrence of Invasive Breast Cancer
Breast Cancer
Primary: Rate of Treatment Regimen Completion — 14 Participants
Phase 2 N=30 Medroxyprogesterone +/- Cyclophosphamide & Methotrexate in Hormone Receptor-Negative Recurrent/Metastatic Breast Cancer
Estrogen Receptor-negative Breast Cancer · Progesterone Receptor-negative Breast Cancer · Recurrent Breast Cancer
Primary: Clinical Benefit Rate (CR + PR + SD > 6 Months). — 7.1; 6.3 Percent of Participants
N/A N=14 Vaccine Therapy in Treating Patients at High Risk for Breast Cancer Recurrence
Breast Cancer
Primary: Safety — 13 participants
Phase 2 N=102 Cetuximab + / - Carboplatin for Estrogen Receptor-Negative, Progesterone Receptor-Negative Metastatic Breast Cancer
Breast Cancer
Primary: Overall Disease Response Rate — 0; 0; 1; 1 Participants
Phase 2 N=21 Pazopanib in Treating Patients With Recurrent or Metastatic Breast Cancer
Breast Cancer · Recurrent Breast Cancer · Stage IV Breast Cancer
Primary: Number of Participants With Partial and Complete Response. — 1 participant
Phase 2 N=76 Pembrolizumab With Carboplatin Compared to Carboplatin Alone in Breast Cancer Patients With Chest Wall Disease
Breast Cancer · Chest Wall Disease
Primary: Disease Control Rate (DCR) at 18 Weeks — 20; 17 percentage of participants
Phase 2 N=48 Neoadjuvant Biweekly Treatment Followed by Weekly Treatment of Breast Cancer
Breast Cancer
Primary: Clinical Response Rate — 47 Participants
Phase 2 N=60 Neoadjuvant Carboplatin, Weekly Abraxane and Trastuzumab in HER2+ Breast Cancer
Breast Cancer
Primary: Number of Patients With Complete Pathologic Response Rate, Observed Following Treatment With q3week Carboplatin, Weekly Abraxane and Weekly Trastuzumab in Resectable and…
Phase 2 N=25 FACBC for Recurrent Prostate Cancer
Recurrent Prostate Cancer
Primary: The Presence of Cancer Tissue Inside of the Prostate Bed — 13; 8; 1; 0 Participants
Phase 2 N=52 Gemcitabine Plus Bevacizumab in Locally Recurrent or Metastatic Breast Cancer
Metastatic Breast Cancer · Locally Advanced Breast Cancer
Primary: Progression Free Survival (PFS) Time — 4.80 months
Phase 2 N=30 ONC201 in Recurrent/Refractory Metastatic Breast Cancer and Advanced Endometrial Carcinoma
Triple Negative Breast Cancer · Endometrial Cancer · Hormone Receptor Positive, HER2 Negative Breast Cancer
Primary: Cohort 1 - Progression-free Survival (PFS) — 1.9 Months
Phase 2 N=17 Carboplatin and Temozolomide (Temodar) for Recurrent and Symptomatic Residual Brain Metastases
Brain Tumor · Brain Metastases
Primary: Affects of Response Rate of Chemotherapy With Intra-arterial Carboplatin and Oral Temozolomide — 42.8 percentage of patients with response
Phase 2 N=118 A Study LY2228820 for Recurrent Ovarian Cancer
Epithelial Ovarian Cancer · Fallopian Tube Cancer · Primary Peritoneal Cancer
Primary: Phase 1b: Recommended Phase 2 Dose of LY2228820 in Combination With Gemcitabine and Carboplatin (Maximum Tolerated Dose [MTD]) — 200 milligrams (mg)
Phase 3 N=2,108 Regional Anesthesia and Breast Cancer Recurrence
Breast Neoplasms
Primary: Number of Participants Who Had Breast Cancer Recurrence After Breast Cancer Surgery — 111; 102 participants — p=0.84
Phase 2 N=17 Vaccine Therapy, Trastuzumab, and Vinorelbine in Treating Patients With Locally Recurrent or Metastatic Breast Cancer
Breast Cancer
Primary: Number of Participants With Response — 0 Participants
Phase 2 N=61 Trastuzumab, Ixabepilone, and Carboplatin in Treating Patients With HER2/Neu-Positive Metastatic Breast Cancer
HER2-positive Breast Cancer · Male Breast Cancer · Recurrent Breast Cancer
Primary: Objective Response for HER2+ Patients (Best Objective Response a Patient Has Ever Experienced on Study) — 3; 13; 10; 11 Participants
Phase 2 N=217 Study Of SU011248 Versus Chemotherapy For Patients With Previously Treated Triple Receptor Negative Breast Cancer
Breast Neoplasms
Primary: Progression-Free Survival (PFS) — 2.0; 2.7; 1.7; 2.5 Months — p=0.8885
Phase 2 N=270 Breast-Conserving Surgery and Radiation Therapy in Patients With Multiple Ipsilateral Breast Cancer
Breast Cancer
Primary: Local Recurrence — 3.1 percentage of participants
Phase 3 N=762 E7389 Versus Treatment of Physician's Choice in Patients With Locally Recurrent or Metastatic Breast Cancer
Breast Cancer
Primary: Overall Survival — 399; 324 Days
Phase 2 N=136 Doxil & Carboplatin Plus HER2+ in Metastatic Breast Cancer
Metastatic Breast Cancer
Primary: Objective Response Rate (ORR) — 30.8; 31.0; 55.6 percentage of participants
Phase 2 N=142 Capecitabine vs. S-1 in Unresectable or Recurrent Breast Cancer
Breast Neoplasms
Primary: Progression Free Survival — 1.2; 1.3 years